PD-L1+ CD14+ monocytes in peripheral blood are correlated with shorter survival in patients treated with anti-PD-1 antibodies, including NSCLC, gastric cancer, melanoma, parotid cancer, and bladder cancer [43]. Here, CD14 is linked to melanoma.